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Abstract
Aim: To evaluate the feasibility of microRNAs (miR) in clinical use to fill in the gap of current methodology commonly
used to test hearing impairment in MELAS patients.
Material and method: A literature review was performed using the following keywords, i.e., MELAS, Hearing Loss, Hearing
Impairment, Temporal Bone, Otoacustic Emission (OTOAE), Auditory Brain Response (ABR), and microRNA. We reviewed the
literature and focused on the aspect of the temporal bone, the results of electrophysiological tests in human clinical
studies, and the use of miR for detecting lesions in the cochlea in patients with MELAS.
Results: In patients with MELAS, Spiral Ganglions (SG), stria vascularis (SV), and hair cells are damaged, and
these damages affect in different ways various structures of the temporal bone. The function of these cells is
typically investigated using OTOAE and ABR, but in patients with MELAS these tests provide inconsistent results, since
OTOAE response is absent and ABR is normal. The normal ABR responses are unexpected given the SG loss in the
temporal bone.
Recent studies in humans and animals have shown that miRs, and in particular miRs 34a, 29b, 76, 96, and 431, can detect
damage in the cells of the cochlea with high sensitivity. Studies that focus on the temporal bone aspects have reported
that miRs increase is correlated with the death of specific cells of the inner ear.
MiR − 9/9* was identified as a biomarker of human brain damage, miRs levels increase might be related to damage in the
central auditory pathways and these increased levels could identify the damage with higher sensitivity and several
months before than electrophysiological testing.
Conclusion: We suggest that due to their accuracy and sensitivity, miRs might help monitor the progression
of SNHL in patients with MELAS.
Keywords: MELAS, Hearing loss, Hearing impairment, Otoacustic emission, Auditory brain response, microRNA, Diagnosis
Background
MELAS, an acronym for myopathy, encephalopathy,
lactic acidosis and stroke like episode syndrome [1], is a
mitochondrial disease that can arise from 10 different
mitochondrial DNA (mtDNA) mutations; in 80% of the
cases it is caused by a 3243A > G point mutation in the
leucine transfer RNA gene [1, 2]. The prevalence of the
3243A > G mutation in Caucasian population it has been
recently re-evaluated and authors identified a 0.24% of
prevalence (236/ 1 00000) [3]. This mutation determines
an alteration in the protein production by mRNA and
change in complexes involved in the respiratory chain (I
and IV) [1]. The alteration in metabolism deriving from
the mitochondrial pathology leads to a multi-organ dis-
ease that involves the ear, as well as muscle, brain, heart,
and pancreas [2].
Hearing disorders in MELAS are progressive and re-
lated to the severity of the mitochondrial disorder [4]. A
large, multi-center study published in 2014 reported that
up to 58% patients with MELAS suffer from SNHL [2],
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whose severity can vary from mild to severe-profound
hearing loss [5, 6] depending on the severity of the
underlying mitochondrial disorder. Among mitochon-
drial disorders, MELAS shows the highest incidence of
hearing loss [2].
Schucknect and Gacek described four forms of
Sensorineural Hearing Loss (SNHL) [7, 8], namely: 1)
Sensory when hair cells are the most affected; this SNHL
form is characterized by a down-sloping audiogram
(Fig. 1a); 2) Neural when SGs are the most damaged
structures; this SNHL form is characterized by a stable
pure tone threshold and a progressive loss of word
discrimination (Fig. 1b); 3) Metabolic when SV is the
most affected structure; this SNHL form shows a flat
or slightly descending pure-tone threshold with good
word discrimination (Fig. 1c); and 4) Cochlear
Conductive when structures different from the ones
described in the other three forms are the origin of
SNHL; this SNHL form is characterized by a gentle
down-sloping threshold [6–8]. Sensory, neural and
metabolic forms of SNHL (and their typical auditory
thresholds) can be caused by a mitochondrial disease,
since mitochondria are present in all types of inner ear
cells, however they are not homogeneously distributed
due to the stochastic segregation; the conductive form
cannot be symptom of MELAS because the structure
prevalently affected is the middle ear- bone part-.
In clinical practice, the progression of SNHL in pa-
tients with MELAS is monitored using a simple pure
auditory test (PTA). The auditory threshold shapes re-
corded during the PTA change depending on which cells
are affected by degeneration. However, due to the high
variability of auditory thresholds in patients with
MELAS [5, 6], this test cannot identify which specific
structure of the cochlea is damaged.
Electrophysiological tests are used in clinical practice
to improve the efficacy of PTA. While they can detect
damage in the cochlea and neural structures, it has been
shown that they cannot evaluate which specific cells of
the inner ear are damaged [5].
A recent animal study by Prasad et al. [9] has shown
that miRs can detect degeneration of the inner ear cells
with considerable specificity, but whether miRs is able to
detect and characterize hearing impairment in humans
has not been thoroughly investigated yet. This review
presents the state-of-the-art on the use of miRs for
SNHL monitoring; we focused our review on patients
with MELAS, where the origin of SNHL in this disease
is well understood.
Main test
Materials and methods
We conducted a literature search on PubMed, Scopus
and Google Scholar using the following keywords:
Fig. 1 The image shows the different shapes as a function of inner ear cells damage as recorded during a pure auditory test. a SensoryNeural Hearing
Loss; b Metabolic hearing Loss; c Neural Hearing Loss
Di Stadio et al. Orphanet Journal of Rare Diseases  (2018) 13:35 Page 2 of 9
“MELAS, Hearing loss, Hearing Impairment, Temporal
Bone, Otoacustic Emission (OTOAE), Auditory Brain
Answer (ABR), and microRNA (miR)”. A total of 250 ar-
ticles were found.
After screening their abstracts, 38 papers were read
entirely, 15 were excluded because not relevant to this
study, and 32 were selected to be included in our review.
Results
Temporal bone aspect and mitochondrial alteration in
patients with MELAS
In patients with MELAS, SV displays severe atrophy that
affects all turns of the cochlea [10]; additionally, the SGs
are reduced in number when compared with SGs in gen-
der- and age-matched healthy subjects [10, 11]. The re-
sidual SV cells show vacuole formation and small dark
cells which are normally not present in the structure; re-
sidual SGs are affected by several degenerative processes
such as loss of cell membrane outline and loss of nuclear
definition [12].
Takahashi et al. [10] reported that Organ of Corti
showed no alterations, and that inner and outer hair
cells were normal in number and function; however,
these findings could be due to the fact that in this study
patients were under 30 years old; unfortunately, other
MELAS temporal bone studies descriptions are scarce.
The greater involvement of SV and SGs compared to
hair cells might be due to the fact that in these struc-
tures the concentration of mitochondria is higher than
in hair cells [13].
Mitochondrial mutations in the temporal bone have
been studied, but the reported rates are inconsistent
across studies. Takahashi et al. reported that SV and
Organ of Corti were the most affected structures,
with a load of mutations between 78% and 85%, re-
spectively [10].
Koda et al. [11], instead, reported a higher mutation
load in SGs than in hair cells and SV and this is partially
consistent with data observed in human temporal bone,
where SV is more affected by damage than SGs. This is
consistent, in part, with the findings reported by Takaha-
shi et al. [10], who in the Organ of Corti observed a mu-
tation load (indicative of mitochondria disorders) higher
than in the SV.
We suggest that these inconsistencies can be explained
by mitotic segregation. The random distribution of mito-
chondria at the time of cell division modifies the distri-
bution of mitochondria [14]; thus, the temporal bone
changes can be very different among patients affected by
MELAS mutation, which might explain the different
phenotypes.
Both MELAS mutation or mtDNA deletion in mito-
chondria modify the production of cytochrome oxidase
complex IV. It has been shown that the resulting
biochemical deficit of cytochrome although not directly
responsible for SG and SV loss, is directly correlated
with an increase of Reactive Oxigens Species (ROS) pro-
duction [15] that induces damage in different parts of
the cochlea. The ROS can act on different structures of
the cochlea thereby damaging SV, SGs and hair cells,
which could further explain the lack of consistency ob-
served in the temporal bone studies [16].
Audiological findings
The auditory tests of patients with MELAS that have
been analyzed in temporal bone studies present flat and
down sloping curves always associated with altered word
discrimination. The auditory tests show a progression in
SNHL correlated with time since mitochondrial disease
onset carries a direct relationship with the aggressiveness
of the pathology [17–20]. The down-ward sloping curve
is observed even when the number of cells of the Organ
of Corti is preserved [12]. This can be explained by a re-
duced function of the hair cells, probably related to the
same degeneration observed in the residual SV and SGs.
SNHL in patients with MELAS is commonly bilateral
[5, 6, 19, 20]; the unilateral form is present only in 2% of
cases [4, 17]. In both forms, SNHL affects high fre-
quency in the onset (75%) and, then involves mild and
low frequency [4–6, 17, 19, 20]; in the remaining 25% of
case SNHL affects all frequencies in its onset [4, 17].
In clinical studies, patients with MELAS are evaluated,
in addition to PTA, with a number of other tests, includ-
ing Transient Evoked Otoacustic Emission (TEOAE) [4],
Otoacustic Emission (OTOAE) [4, 17], Auditory Brain
Response (ABR) [4, 5, 17], Psycoacusting Tuning Curves
(PTC) [5], Distortion Product Otoacustic Emission
(DPOAE) [6, 17], electrocochleography [6, 17], and
electrically-evoked compound action potentials [5].
Zwirner et al. [4] observed that MELAS patients suf-
fered from a mild form of SNHL affecting the high fre-
quencies [18] and from moderate to severe SNHL forms
involving all frequencies. The word recognition test
score was normal in subjects with mild SNHL and ab-
normal in subjects with moderate to severe SNHL, with
a score depending on the SNHL severity. Patients with
SNHL with a loss of 40 dB showed normal OTOAE;
those with moderate to severe SNHL presented no
OTOAE response. In this study, ABR was recorded
using a stimulus that consisted of alternating clicks
presented at a rate of 16.7/s and were generated by
square-wave electrical pulses of 0.1 milliseconds dur-
ation. Stimuli were presented monaurally at 80, 90, and
100 dB normal Hearing Level (nHL). Average values of
2000 trials were obtained on stimulation of each ear. In
all patients, ABR was normal in latency and amplitude.
Kullar et al. [5] reported that 8/11 MELAS patients
with mutation m3243A > G suffered from SNHL, which
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ranged from mild/moderate hearing loss in high fre-
quencies (5/11 patients) to severe/profound hearing loss
(3/11 subjects) spanning all frequencies. These results
can be described in terms of the auditory threshold
shapes described above, and summarized by both flat
and down-ward sloping curves (Fig. 1). Those patients
showed complete absence of TEOAEs in all forms of
SNHL, reflecting a completely loss of function in
outer hair cells. In this study, ABR was recorded
using a click stimulus with alternating polarity deliv-
ered at a suitable sensation level to give a clear re-
sponse. The sensation level was predetermined by the
mean hearing level from each ear at 2/4 kHz: 440 dB
Hearing Level (HL) used click stimulus at 70 dB nHL, 40–
60 dB HL used click stimulus at 80 dB nHL, and 460 dB
HL used click stimulus at 90 dB nHL. Contralateral
masking was applied when required. In two of the 3
patients with profound SNHL, the ABR was not re-
cordable; in the remaining patients, ABR waves
displayed normal latency and amplitude even in pa-
tients with SNHL. PTC, which allows functional
evaluation of inner and outer hair cells at the same
time, showed no tip shifts in patients with normal
hearing and mild SNHL; shifts at 1 kHz were ob-
served in patients with moderate to severe SNHL in
66% of cases. The shift at 1 kHz indicates complete
loss of inner and outer hair cells in the middle turn
of the cochlea (Fig. 2).
Santarelli et al. [6] analyzed data from 10 patients with
MELAS. They reported a flat threshold curve in all pa-
tients. Only 20% of subjects suffered from severe to pro-
found SNHL, while the remainder of patients showed
mild to moderate SNHL. DPOAE were detected in 1 ear
in 6 out of 10 (60%) of patients. DPOAE responses were
identified only at low frequencies in 3 out of the 6 sub-
jects. The DPOAE testing results indicate that outer hair
cells function is preserved in some portion of the coch-
lea, and in particular in HCs in basal turn. One of the
two patients with severe to profound SNHL showed pre-
served DPOAE in both ears, but the ABR waves were
not detectable.
Electrocochleography showed normal results in both
ears in terms of potential peak amplitude but, the po-
tential displayed lower amplitude when compared
with potentials recorded from patients with normal
hearing. In the other MELAS patients (i.e., patients
with moderate SNHL) electrocochleography testing
showed potentials similar to those recorded from nor-
mal hearing subjects in terms of peak amplitude,
while the evoked potential was altered and resembled
the shape typically recorded from patients with hear-
ing impairment.
Fig. 2 Two methods are used for investigating the hearing pathways. Cochlear function is investigated by OTOAE/TEOAE/DPOAE (which can
identify the hair cells damage). The retro-cochlear portion is investigated by ABR. The table on the left shows the area that generates the specific
wave; the image shows the area and the wave
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Sue et al. [17] analyzed 20 patients with MELAS and
found moderate to profound SNHL in 78% of patients.
The auditory threshold presented a down-ward curve at
the onset of SNHL, which then became flat with the dis-
ease progression and aging. Only 50% of patients dis-
played normal speech recognition, suggesting a good
retro-cochlear function. ABR was performed using a rar-
efaction click stimuli; stimulus intensity was at 65 to
70 dB above hearing thresholds or at maximal stimulator
output (110 dB) if the hearing threshold was above
40 dB. ABR showed absent or delayed wave I in one ear
at least in 61% of patients, but waves III and V were al-
ways present. Electrocochleography was performed in 11
patients and the test result was found to be normal in
64% of patients; ABR was not recordable from two pa-
tients and in the last two the click evoked electroco-
chleogram was broad. DPOAE were not detectable when
observed in the range of frequency interested by severe
to profound SNHL in 7/11 patients, but responses were
present and electrically recordable when the SNHL was
within 40 dB.
In the study by Vandana et al. [19], 6 children and
2 adults with MELAS were investigated; 3 out of 8
patients suffered from moderate to severe SNHL; in
two cases the SNHL was subclinical; 1 presented a
mild SNHL. All patients presented a down-ward slop-
ing curve and OTOAE were absent in 50% of sub-
jects. Auditory evoked potentials were recorded using
a standard protocol. Only in 1 patient ABR showed
absence of signal, which is indicative of retrocochlear
disease.
In a large cohort study, Iwanicka-Pronicka et al. [20]
showed that the shapes of PTA were correlated with
specific mitochondrial mutations. They observed a
down-ward sloping curve in patients with m.1555A > G
and a pantonal shape with slight down-ward sloping at
the high frequencies in the patients with mutation
3243A > G. Their results were statistically significant
(p < 0.05). A prevalence of moderate SNHL was ob-
served in m.3243A > G, and the 97% of patients with
this mutation had a family history of hearing loss.
Overall, the studies described above show the limita-
tions of the pure tone auditory test and of the electro-
physiological tests. A comparative analysis of results
highlighted that there are major inconsistencies between
the outcome of OTOAE/TEOAE/DPOAE and ABR
testing.
The presence of OTOAE/TEOAE waves were reported
even for SNHL with threshold higher of 40 dB [4, 5],
where absence of response would be expected. Other
studies showed absence of OTOAE/TEOAE response
only when SNHL is moderate to severe (> 40 dB) [4, 19].
ABR waves follow a similar trend. Some studies de-
scribed either normal latency and amplitude in presence
of moderate to severe SNHL [3, 18], or instead reported
absent in mild forms of SNHL [4, 5, 16].
MicroRNAs
MicroRNAs (miRs) are endogenous, small sequences of
non-coding RNA [21], that have been shown to modu-
late a wide range of biological function. MiRs regulate
post transcriptional mRNA expression binding the 3′-
untraslated region of the complementary mRNA sequence
and acting as gene modulator [22]. Change in their con-
centration has been observed in several diseases, including
inflammation and aging [23]. miR levels increasing are
specifically related to the damaged structure [22]. Their
levels associated to hearing disorders have been investi-
gated [24–27] using miRs, which, due to their high stabil-
ity in blood, can be easily identified [25].
We speculate that miR levels can be the expression of
damage but at the same time they might influence the
mitochondrial metabolism by acting on it; they could
downregulate the Sirtuin (SIRT1) action by increasing
ROS [24], suppress the function of Blc-2 by increasing
the apoptosis in cells [25], or increase the function of
Bak by causing cell death through increased apoptosis
[26] (Fig. 3), and then they might modulate the expres-
sion of specific genes by increasing apoptosis [28]. The
increase of miRs 34a, 29b, 76, 96, 183 and 431 have been
identified as potential markers of hearing damage in ani-
mal studies [21–26]; among them, only miR34a has been
validated in humans [27].
In humans, miR34a increase has been found to be cor-
related with hearing loss in aging. In particular, its con-
centration in blood is anti-correlated with the scores of
Pure Tone Averages testing [24]. miRs s16- 5p, 24-3p,
and 185-5p were identified in subjects with SNHL ex-
posed to noise and the increase in their levels was corre-
lated with the severity of SNHL [23].
miR increase was directly correlated with reduced re-
sponses or completely absence of OTOEA; when the
hearing damage was electrically identified, the miR 34a
and miR-29b levels were also increased in blood [24, 25],
showing a specific correlation between the miRs level
and the altered response in OTOAE.
The miRs that express cochlear damage are very
specific for each structure as shown in Fig. 4, but so
far only miRs sensitive to general damage (miR 76) or
to hair cells and/or SG damage 34a 96 have been
tested in humans.
Jong et al. identified the role of miR-299-3p in the
aging vessel process [29] but, until today, nobody use it
to evaluate the function of stria vascularis both in
animal or human studies; we think that it could be
useful due to similar cells present in both structures
(vessel and SV).
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Meseguer et al. [30] showed the power of miR − 9/9*as
a detector of brain damage in humans. Using cybrids
from two patients affected from mutation 3243A > G
and m8344 A > G, they found that the overexpression of
this small molecule was able to increase the mitochon-
drial dysfunction in MELAS and at the same time pro-
vide a measure of brain degeneration. We think that this
miR could be helpful to investigate the SNHL in the ret-
rocochlear portion due to its possible increased level
when a brain degeneration is ongoing.
In conclusion, the studies described above suggest that
miRs can help identify the cells involved in SNHL.
Change in miR levels is the expression of cells damage
but at the same time miRs can directly modulate the
mitochondria metabolism by increasing apoptosis.
Discussion
Our review identifies the limitations of current clinical
method used to evaluate SNHL in MELAS due to the in-
congruences with the temporal aspect. We suggest to
use miRs that could identify the damage that affects the
inner ear cells and central hearing pathways with high
sensitivity and specificity.
miRs have been proposed as detector of damage in
hair cells as well as SGs and SV, which, according to
Fig. 3 The image summarizes the mechanisms regulated by miR 34 a able to determine the damage of the inner ear structures. From top to bottom:
Stria Vascularis, Organ of Corti with hair cells, and Spiral Ganglions in the human temporal bone
Fig. 4 The image shows the details on miR and the structure of the inner ear that,when damaged, can change their levels in blood of patients
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temporal bone studies, are the most damaged structures
when SNHL is present in patients with MELAS [10, 11].
In patients with MELAS, SNHL progression is typic-
ally first tested with PTA (which is used for screening
purposes) and then with OTOAE/DPOAE/TEOAE and
ABR (for a more thorough evaluation).
PTA testing alone is not specific enough to identify
which cells of the inner ear are affected by the disease.
The low PTA sensitivity is due to the variability of audi-
tory thresholds observed in patients with MELAS (which
is related to the severity of the mitochondrial disease
and time from disease onset [17–20]) as well as to a
limitation of the methodology, namely the operator/ pa-
tient bias which can lead to a difference of approxi-
mately 5 to 10 dB between the actual hearing ability and
recorded response.
OTOAE/DPOAE/TEOAE are valid methods to inves-
tigate hair cells function [31] and can provide an esti-
mate of which turn of the cochlea suffers from cells loss
[6, 7, 17]; however, they cannot evaluate the state of SV.
In fact, DPOAE/TEOAE only assess SV in an indirect
fashion [6], by measuring the response of hair cells;
unfortunately, this indirect method provides results
that are not specific enough so it is unable to quantify
the actual severity of SV damage. SV (the vascular
apparatus of the cochlea) is present in any turn of the
cochlea; its atrophy is measured as percentage of “lost
area”. When metabolic SNHL occurs, at least 30% of
VS is lost, which leads to considerable VS damage [1].
With time, this damage causes hair cells death. The
indirect evaluation of SV by DPOAE/TEOAE can delay
the diagnosis and lead to an underestimation of the
actual damage.
Another limitation of OTOAE/DPOAE/TEOAE is due
to the fact that these tests can identify cells damage only
when SNHL threshold is over 40 dB; thus, they cannot
detect mild SNHL. The identification of SNHL onset
(and thus of mild forms of SNHL) is extremely import-
ant in MELAS because the use of antioxidant molecules
might slow down the progression of the disease and
stimulate recovery [4].
SG function is investigated with the word recognition
(WR) test, typically followed by the ABR. WR cannot in-
form on SGs’ damage for two reasons. First, a loss of at
least 70% of SGs is necessary to lead to a reduction in
the percentage of WR that is classifiable as abnormal [6];
second, brain structures (which are necessary for speech
recognition [32]) could compensate for the reduction of
SGs, especially if brain function is fully preserved.
ABR allows to investigate the hearing pathway from SG to
the auditory cortex. Each wave recorded as a response to
the test assesses the function of a specific area (Fig. 2). A
damage in a specific area of the hearing pathways is
reflected by a change in ABR amplitude and/or latency.
Normal ABR waves have been found in patients with
MELAS [5, 6]. This finding is not consistent with the
data reported in temporal bone studies [5, 6, 8, 10, 15]
that have shown that SGs are reduced in number or
present anatomical abnormalities inconsistent with
normal function, as well as with the damage caused by
stroke in MELAS. Instead, in patients with MELAS we
expect to see abnormal ABR latencies, at least. Normal
ABR waves are not consistent with clinical observa-
tions and the findings observed in human temporal
bone.
The inconsistencies are probably due to several causes.
A key cause is probably the low specificity of waves I in
identifying which structures are affected by damage.
Waves I record the electrical potentials associated with
the global activity of hair cells synapsis, SGs and coch-
lear nerve; thus, isolating the contribution of the SG
damage alone is difficult. This difficulty is compounded
by signal amplification by the cochlear nerve. After the
cochlear nerve, the signal travels upward and reaches
the cochlear nucleus (wave III), the superior olivar com-
plex (wave IV) and lateral lemniscus (wave V). The dam-
age due to a stroke or metabolic dysfunction needs to
involve a wide area of the auditory pathways in order to
determine a change in the ABR response, similar to what
happens with ABR response and SG damage.
The limitations of the electrophysiological tests de-
scribed above highlight the need of identifying an alter-
native, more specific method to investigate the hearing
pathways. This could be especially beneficial for patients,
like MELAS patients, where the progression of the hear-
ing impairment can be slowed down via pharmacological
(for example antioxidant) therapy if diagnosis is made
early.
MiRs have been shown to be very specific and highly
sensitive to identify cellular damage in the cells of the
inner ear [24–27], vascular structure [29] and superior
hearing pathways [30].
The validity of miRs 34a and 29b as identifiers of hair
cells and SG damage is supported by human studies that
identified also the presence of miRs s16- 5p, 24-3p, and
185-5p in subjects exposed to noise and exhibiting
SNHL without specific correlation with damaged inner
ear structure.
miR-299-3p was identified in humans and correlated
to vascular degeneration [29]; we speculate that this miR
can help evaluate SV degeneration in SNHL. In fact, SV
(the vascular apparatus of the inner ear) contains cells
similar to the ones in other vessels and damage in this
structure could be identified by the same miR that is
found to be increased in aging vessels.
MiR 431 has been shown to be sensitive to the de-
crease of SGs; thus it could potentially be used to in-
crease the specificity of miR 34a and 29b.
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Conclusion
Our literature review suggests that the levels of mRNAs
34a, 29b, 299-3p and 431 might be used to measure
inner ear degeneration (Table 1).
This measure could potentially identify the origin of
SNHL for instance by miR-9/9*, which has already been
identified as a marker of brain degeneration in patients
with MELAS might be used to identify the damage in
central hearing pathways in the retro-cochlear portion
due to its increased level occurring during a process of
brain degeneration.
Thanks to their sensitivity and quick response to the
change in cells conditions we speculate that miRs might
help to assess the effect of antioxidant pharmacological
therapy on neural structures. The validity of circulating
miR to identify the subtype of Amyotrophic Lateral
Sclerosis was previously demonstrated by our group [33].
We have focused our review on patients with MELAS,
because in such pathology SNHL and mitochondrial al-
teration are intimately related.
MELAS patients -where the damage is related to a
mitochondrial alteration- can serve as a model to inves-
tigate the accuracy of miRs in identifying which cells are
damaged, since we infer that the most affected cells are
the ones with higher concentrations of mitochondria
(SV and SGs). The validity of miRs measurements after
confirmed by this model could be applied to evaluate
the damage in other forms of SNHL.
Our literature review suggests that miRs might be used
to detect damage in the hearing pathways of MELAS pa-
tients, especially early on in the disease when SNHL
starts manifesting. If early detected, SNHL might be suc-
cessfully treated with antioxidants [19].
MiRs can be detected in blood, thus sample collection
can be easily performed. While miR analysis might in-
crease the cost of monitoring SNHL, we note that
mRNAs analysis in patients with rare diseases is widely
accepted.
MiRs 34a, 29b, 299-3p and miR431 and − 9/9* might
be particular useful for monitoring SNHL, as they can
identify which cells are more affected by mitochondrial
degeneration both peripherally (inner ear) and centrally
(from nuclei to cortex).
MiRs might be used in conjunction with electro-
physiological tests to enhance their efficacy for identify-
ing specific cells damage in MELAS.
Future work should focus on testing more carefully
their accuracy in humans and investigating to what ex-
tent miRs can be used to evaluate SNHL forms that have
a different origin.
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